Review ArticlePoint-of-Care Testing at the Disaster–Emergency–Critical Care InterfaceTran, Nam K. PhD, MS, FACB; Godwin, Zachary BS; Bockhold, Jennifer; Kost, Gerald J. MD, PhD, MS, FACBAuthor Information From the Department of Pathology and Laboratory Medicine, University of California, Davis, School of Medicine, Davis, CA. Reprints: Nam K. Tran, PhD, MS, FACB, 3435 Tupper Hall, Department of Pathology and Laboratory Medicine, University of California, Davis, School of Medicine, Davis, CA 95616. E-mail: [email protected]. Manuscript support was provided through the University of California, Davis, Point-of-Care Testing Center for Teaching and Research and the National Institute of Biomedical Imaging and Bioengineering Point-of-Care Technologies grant (U54 EB007959; Gerald J. Kost, MD, PhD, MS, FACB, principal investigator, National Institutes of Health). This content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institute of Biomedical Imaging and Bioengineering or the National Institutes of Health. The authors declare no conflict of interest. Point of Care: The Journal of Near-Patient Testing & Technology: December 2012 - Volume 11 - Issue 4 - p 180-183 doi: 10.1097/POC.0b013e318265f7d9 Buy Metrics Abstract Point-of-care testing allows for medical testing to be performed across the disaster–emergency–critical care continuum. The disaster–emergency–critical care continuum begins with the identification of at-risk patients, followed by patient stabilization, and ultimately transfer to an alternate care facility or mobile hospital for comprehensive critical care. Gaps at the interfaces for each of these settings lead to excess mortality and morbidity. Disaster victims are at risk for acute myocardial infarctions, acute kidney injury (AKI), and sepsis. However, cardiac biomarker testing, renal function testing, and multiplex rapid pathogen detection are often unavailable or inadequate during disasters. Cardiac biomarker reagents require refrigeration; traditional renal function tests (ie, serum creatinine) exhibit poor sensitivity for predicting AKI in critically ill patients, and culture-based pathogen detection is too slow to help initiate early-directed antimicrobial therapy. We propose 3 value propositions detailing how rapid, point-of-care, and environmentally hardened cardiac biomarker, AKI, and multiplex pathogen testing harmonize the interface between disaster, emergency, and critical care. © 2012 Lippincott Williams & Wilkins, Inc.